<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919815</url>
  </required_header>
  <id_info>
    <org_study_id>ITCRBY24-T1RA</org_study_id>
    <nct_id>NCT00919815</nct_id>
  </id_info>
  <brief_title>Ciclosporin in the Management of New Type 1 Reactions in Leprosy</brief_title>
  <official_title>A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Homes and Hospitals of St Giles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alert Hospital, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armauer Hansen Research Institute, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 1A: Ciclosporin in the management of new Type 1 Reactions in Leprosy

      Objective: A randomised double blind controlled trial comparing Ciclosporin and
      Prednisolone,to determine whether treatment with Ciclosporin gives the same outcome in the
      treatment of new Type 1 Reactions as Prednisolone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We tested our hypothesis that ciclosporin would be as effective as prednisolone in the
      treatment of patients with leprosy reactions and nerve function impairment and that patients
      treated with ciclosporin would have fewer side effects than patients treated with
      prednisolone. A randomised controlled trial comparing ciclosporin and prednisolone in the
      treatment of acute leprosy T1R was conducted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in nerve function and Clinical Severity Score</measure>
    <time_frame>at week 4, 20, 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of T1R recurrence episodes per patient in each treatment arm</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of T1R recurrence for patients in each treatment arm</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extra prednisolone needed to control reaction</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Difference in score in Quality of Life assessment between start and end of treatment for patients in each treatment arm</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to recurrence of T1R for patients in each treatment arm</measure>
    <time_frame>up to 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Leprosy</condition>
  <arm_group>
    <arm_group_label>ciclosporin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard course of prednisolone given in a reducing regimen over 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <description>Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)</description>
    <arm_group_label>ciclosporin arm</arm_group_label>
    <other_name>Cyclosporine</other_name>
    <other_name>Cyclosporine A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>prednisolone 40mg daily then reducing regimen over 24 weeks</description>
    <arm_group_label>prednisolone</arm_group_label>
    <other_name>corticosteroids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with clinical evidence of T1R with new nerve function impairment (NFI).

          -  Aged 18-65

          -  Weigh more than 30Kg

        Exclusion Criteria:

          -  Unwillingness to give informed consent

          -  Patients with severe active infections such as tuberculosis

          -  Pregnant or breastfeeding women (see Appendix II)

          -  Those with renal failure, abnormal renal function, hypertensive

          -  Patients taking thalidomide currently or within the last 3 months

          -  Patients not willing to return for follow-up

          -  Women of reproductive age not willing to use contraception for the duration of the
             study ( see Appendix II)

          -  HIV positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Lockwood, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alert Hospital</name>
      <address>
        <city>Addis Abeba</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>March 21, 2015</last_update_submitted>
  <last_update_submitted_qc>March 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>London School of Hygiene and Tropical Medicine</investigator_affiliation>
    <investigator_full_name>Saba Lambert</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Leprosy</keyword>
  <keyword>Type 1 Reactions</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Ciclosporin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leprosy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

